
Keywords: ADA, Adenosine deaminase; ADA-SCID, ADA deficient SCID; CBA, Cost-benefit analysis; CEA, Cost-effectiveness analysis; DBS, Dried blood spot; ERT, Enzyme replacement therapy; HCT, Hematopoietic cell transplantation; ICER, Incremental cost-effectiveness rat